Items of Business

1. To elect 12 members of the Board of Directors, each until our next Annual Meeting and until his or her successor has been duly elected and qualified.
2. To ratify the selection of KPMG LLP as our independent registered public accounting firm for 2024.
3. To approve the Amended and Restated Pfizer Inc. 2019 Stock Plan.
4. To conduct an advisory vote to approve our executive compensation.
5. To consider 4 shareholder proposals, if properly presented at the Annual Meeting.
6. To transact any other business that properly comes before the Annual Meeting or any adjournment or postponement of the Meeting.

Materials To Review

This booklet contains our Notice of 2024 Annual Meeting and Proxy Statement. Our 2023 Annual Report on Form 10-K is included as Appendix A and is followed by certain Corporate and Shareholder Information. None of Appendix A or the Corporate and Shareholder Information on the back inside cover are a part of our proxy solicitation materials.

This Notice of 2024 Annual Meeting and Proxy Statement and a proxy card or voting instruction form are being mailed or made available to shareholders starting on or about March 14, 2024.

Margaret M. Madden

Senior Vice President and Corporate Secretary, Chief Governance Counsel
March 14, 2024